Key Highlights

  • Onconetix shares are trading 18.02% higher at $0.56 on Wednesday, October 28, 2026, from an implied prior close near $0.47 (calculated).
  • A 1-for-10 reverse stock split was announced on October 26, 2026 and is expected to take effect at 12:01 a.m. Eastern on November 6, 2026.
  • About 5,886,774 shares were outstanding on October 21, 2026, which would fall to roughly 588,677 after the split.
  • Onconetix has advanced $3.0 million of an up to $5.0 million bridge facility to Realbotix, including $500,000 on October 23, 2026.
  • Cash was $5.94 million on June 30, 2026, and the latest quarterly filing carries a going-concern warning.

Onconetix Price Move: Why Is This Penny Stock Among the Most Active Today?

Onconetix (NASDAQ:ONCO) shares are trading 18.02% higher at $0.56 on Wednesday, October 28, 2026, among the most heavily traded names priced at $5 or less. The implied prior close is about $0.47 (calculated). No dated company release on October 28 accompanies the advance.

The jump follows an unsettled week. Shares closed at $0.41 on October 22, 2026, inside a 52-week range of $0.38 to $200.00 that reflects several reverse splits. On October 23 the company disclosed a further $500,000 advance to Realbotix, and on October 26 it announced another reverse split.

Onconetix is a commercial-stage company built around Proclarix, a blood test used to assess prostate cancer risk and approved for sale in the European Union. It depends on Labcorp (NYSE:LH) to market and sell the test. Revenue was just $17,120 in the second quarter of 2026 and $38,577 for the first half.

Onconetix Reverse Split: What Changes on November 6, 2026?

On October 26, 2026, Onconetix said it would carry out a 1-for-10 reverse stock split, expected to take effect at 12:01 a.m. Eastern on November 6, 2026. The ticker remains ONCO, and fractional shares will be paid in cash. The release does not state a reason for the split.

About 5,886,774 shares were outstanding on October 21, 2026, which would become roughly 588,677 after the split. The company also split 1-for-5 on March 25, 2026 and 1-for-10 in May 2026.

Onconetix and Realbotix: How Far Does $3.0 Million of Bridge Funding Go?

On February 12, 2026, Onconetix announced a share exchange agreement to acquire 100% of Realbotix in an all-stock transaction. Realbotix, a subsidiary of a Canada-listed parent,, develops AI-powered humanoid robots made in the United States.

To support the deal, Onconetix announced a bridge facility on September 14, 2026 that allows up to $5.0 million of loans. The October 23 advance of $500,000 brought principal outstanding to $3.0 million. The loans carry no interest until closing, when the note is cancelled in full, and interest of 12% a year applies if the agreement is terminated.

Closing requires approval from Onconetix shareholders and regulators, plus a Form S-4 filing.

Cash was $5.94 million on June 30, 2026, and the net loss was $2.87 million for the second quarter. The filing states substantial doubt about the company's ability to continue as a going concern, with an accumulated deficit of about $138.3 million.

What to Watch Next: The Split Date, the Third-Quarter Report and the S-4

The reverse split is expected on November 6, 2026, and the third-quarter report is estimated for around November 12, 2026. Further bridge advances, the S-4 filing and the shareholder vote will show how the Realbotix transaction is progressing.